PT  - JOURNAL ARTICLE
AU  - Patel, Aniruddh P.
AU  - Paranjpe, Manish D.
AU  - Kathiresan, Nina P.
AU  - Rivas, Manuel A.
AU  - Khera, Amit V.
TI  - Race, Socioeconomic Deprivation, and Hospitalization for COVID-19 in English participants of a National Biobank
AID  - 10.1101/2020.04.27.20082107
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.04.27.20082107
4099  - http://medrxiv.org/content/early/2020/05/02/2020.04.27.20082107.short
4100  - http://medrxiv.org/content/early/2020/05/02/2020.04.27.20082107.full
AB  - Preliminary reports suggest that the Coronavirus Disease 2019 (COVIDâ^’19) pandemic has led to disproportionate morbidity and mortality among historically disadvantaged populations. The extent to which these disparities are related to socioeconomic versus biologic factors is largely unknown. We investigate the racial and socioeconomic associations of COVIDâ^’19 hospitalization among 418,794 participants of the UK Biobank, of whom 549 (0.13%) had been hospitalized. Both black participants (odds ratio 3.4; 95%CI 2.4â^’4.9) and Asian participants (odds ratio 2.1; 95%CI 1.5â^’3.2) were at substantially increased risk as compared to white participants. We further observed a striking gradient in COVIDâ^’19 hospitalization rates according to the Townsend Deprivation Index â^’ a composite measure of socioeconomic deprivation â^’ and household income. Adjusting for such factors led to only modest attenuation of the increased risk in black participants, adjusted odds ratio 3.1 (95%CI 2.0â^’4.8). These observations confirm and extend earlier preliminary and lay press reports of higher morbidity in non-white individuals in the context of a large population of participants in a national biobank. The extent to which this increased risk relates to variation in pre-existing comorbidities, differences in testing or hospitalization patterns, or additional disparities in social determinants of health warrants further study.Competing Interest StatementA.V.K. has served as a consultant to Sanofi, Medicines Company, Amgen, Maze Pharmaceuticals, Navitor Pharmaceuticals, and Color Genomics; received speaking fees from Illumina, the Novartis Institute for Biomedical Research; received sponsored research agreements from the Novartis Institute for Biomedical Research and IBM Research, and reports a patent related to a genetic risk predictor (20190017119). The remaining authors have no disclosures.Funding StatementFunding support was provided by grant T32HL007208 from the National Heart, Lung, and Blood Institute (to A.P.P.), grant 5U01HG009080 from the National Institutes of Health Center for Multi- and Trans-ethnic Mapping of Mendelian and Complex Diseases (to M.A.R.), a Merkin Institute Fellowship from the Broad Institute of MIT and Harvard (to A.V.K.), grant 1K08HG010155 (to A.V.K.) and 5R01HG01014002 (to M.A.R.) from the National Human Genome Research Institute, a Hassenfeld Scholar Award from Massachusetts General Hospital (to A.V.K.), and a sponsored research agreement from IBM Research (to A.V.K.). Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is made available from the UK Biobank to researchers from universities and other research institutions with genuine research inquiries following IRB and UK Biobank approval.